Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ENTPD5 | O75356 | 2/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546007 | 0.81 | MAPT (0.60) | MAPTENTPD5CETPPTPN1AKT1 | |
| SCHEMBL4417328 | 0.79 | BACE1 (0.37) | MAPT | |
| SCHEMBL1506790 | 0.77 | RXRA (0.50) | MAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL9737788 | 0.76 | — | — | |
| SCHEMBL23618118 | 0.75 | PPARA (0.47) | MAPTENTPD5CETPPTPN1AKT1 | |
| SCHEMBL6130742 | 0.74 | AKT1 (0.42) | MAPTENTPD5CETPPTPN1AKT1 | |
| SCHEMBL888447 | 0.73 | TSHR (0.39) | MAPTALDH1A1CYP3A4DRD2 | |
| SCHEMBL4458326 | 0.72 | MAPT (0.43) | MAPTENTPD5CETPPTPN1AKT1 | |
| SCHEMBL8423372 | 0.72 | PKM (0.36) | HIF1AEPAS1 | |
| SCHEMBL3184205 | 0.71 | AKT1 (0.56) | MAPTENTPD5CETPAKT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102596982-B | Peritoneal thickening inhibitor | CCI CORP | 2015-03-18 | — | — | CN | claimed |
| CN-111032636-B | 6-chromanol derivative and synthesis thereof | 帝斯曼知识产权资产管理有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-11006626-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2021-05-18 | — | — | US | disclosed |
| US-20210024485-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2021-01-28 | — | — | US | disclosed |
| US-10676452-B2 | Compound for the prophylaxis or treatment of organ damage | SULFATEQ B.V. (NL) | 2020-06-09 | — | — | US | disclosed |
| CN-111032636-A | 6-chromanol derivatives and synthesis thereof | 帝斯曼知识产权资产管理有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10426771-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | SULFATEQ B.V. (NL) | 2019-10-01 | — | — | US | disclosed |
| US-20190098890-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2019-04-04 | — | — | US | disclosed |
| US-10123529-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2018-11-13 | — | — | US | disclosed |
| EP-2701695-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | Retrotope, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2595957-A1 | PYRIDIN- 2 - YL SULFANYL ACID ESTERS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131350-A1 | PYRIDIN-2YL SULFANYL ACID ESTERS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-05-23 | — | — | US | disclosed |
| CN-101679188-B | Transportation of a monomer composition in a transport means or pipe | BASF SE | 2013-01-30 | — | — | CN | disclosed |
| WO-2012148926-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012011123-A1 | PYRIDIN- 2 - YL SULFANYL ACID ESTERS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-01-26 | — | — | WO | disclosed |
| CN-101679188-A | Monomer composition is in transportation means or ducted transportation | BASF SE | 2010-03-24 | — | — | CN | disclosed |
| EP-1727780-A1 | PROCESS FOR PREPARING (METH)ACRYLIC ESTERS. | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005082828-A1 | METHOD FOR THE PRODUCTION OF (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-09 | — | — | WO | disclosed |
| WO-2000010994-A1 | PROCESS FOR THE PREPARATION OF 2-(ARYLOXYMETHYL)-2,5,7,8-TETRAMETHYLCHROMAN-6-OLS | SANKYO COMPANY, LIMITED (JP) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11006626-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | MAPT 4696/4885ENTPD5 2964/4885CETP 643/4885 |
| US-20190098890-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | MAPT 4696/4885ENTPD5 2964/4885CETP 643/4885 |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | MAPT 4696/4885ENTPD5 2964/4885CETP 643/4885 |
| US-20130131350-A1 | PYRIDIN-2YL SULFANYL ACID ESTERS AND PROCESS FOR THE PREPARATION THEREOF | VCAM1, ICAM1, CCL5 | MAPT 4815/4885ENTPD5 3786/4885CETP 3773/4885 |
| US-10676452-B2 | Compound for the prophylaxis or treatment of organ damage | GLS, TXN2, SLC5A2 | MAPT 4602/4885ENTPD5 421/4885CETP 1681/4885 |
| US-20210024485-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | GLS, TXN2, SLC5A2 | MAPT 4602/4885ENTPD5 421/4885CETP 1681/4885 |
| US-10426771-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | CFTR, HRH2, HRH4 | MAPT 3431/4885ENTPD5 574/4885CETP 2874/4885 |
| US-10123529-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | MAPT 4696/4885ENTPD5 2964/4885CETP 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.